Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qol Holdings CoTSE:3034 +0.88%88 Debt-to-EBITDA is 0.63 as of Mar. 2026, which is 70% below its 10-year median of 2.07. GuruFocus rates TSE:3034 with a GF Score™ of 88/100 and a GF Value™ of 円2,300.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 480 Healthcare Providers & Services companies, Qol Holdings Co ranks better than 61.87% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Qol Holdings Co's Debt-to-EBITDA or its related term are showing as below:
TSE:3034'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.41 Med: 2.07 Max: 3.11
Current: 1.41
During the past 13 years, the highest Debt-to-EBITDA Ratio of Qol Holdings Co was 3.11. The lowest was 1.41. And the median was 2.07.
TSE:3034's Debt-to-EBITDA is ranked better than 61.87% of 480
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs TSE:3034: 1.41
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Qol Holdings Co Debt-to-EBITDA Related Terms
Qol Holdings Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Qol Holdings Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qol Holdings Co Debt-to-EBITDA Competitor Comparison
For the Pharmaceutical Retailers subindustry, Qol Holdings Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qol Holdings Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qol Holdings Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Qol Holdings Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Qol Holdings Co (TSE:3034) has a Debt-to-EBITDA of 0.63 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Qol Holdings Co. This is 70% below median its historical median of 2.07. Over the past decade, Qol Holdings Co's Debt-to-EBITDA has ranged from 1.41 to 3.11. According to the industry distribution chart, Qol Holdings Co ranks #183 out of 480 companies in the Healthcare Providers & Services industry, placing it in the top 38.1%.
Is Qol Holdings Co's Debt-to-EBITDA too high?
Qol Holdings Co's current Debt-to-EBITDA of 0.63 is 70% below median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 3.11. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Qol Holdings Co's value of 0.63 is 71.2% below this industry median. Based on the distribution chart, Qol Holdings Co ranks #183 out of 480 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Qol Holdings Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Qol Holdings Co's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qol Holdings Co ranks #183 out of 480 companies for Debt-to-EBITDA. This puts Qol Holdings Co in the upper half of its industry. The industry median Debt-to-EBITDA is 2.19. Qol Holdings Co's value of 0.63 is 71.2% below this benchmark. Historically, Qol Holdings Co's own Debt-to-EBITDA has ranged from 1.41 to 3.11 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 2.19, Qol Holdings Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qol Holdings Co's current Debt-to-EBITDA of 0.63 is 71.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Qol Holdings Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qol Holdings Co's current Debt-to-EBITDA is 0.63, which is 70% below median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qol Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Qol Holdings Co (TSE:3034) is currently considered Fairly Valued. The stock's GF Value™ is 円2,300.17, compared to a current price of 円2,532.00 — trading 10.1% above its estimated fair value. The current Debt-to-EBITDA is 0.63, which is 70% below median its 10-year median of 2.07 and 71.2% below the Healthcare Providers & Services industry median of 2.19. Qol Holdings Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Qol Holdings Co (TSE:3034), the current Debt-to-EBITDA is 0.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qol Holdings Co (TSE:3034) Overvalued in 2026?
Based on GuruFocus' analysis, Qol Holdings Co stock appears to be overvalued.
The current stock price of 円2,532.00 is trading 10.1% above its estimated GF Value™ of 円2,300.17.
GuruFocus considers Qol Holdings Co to be Fairly Valued.
Key valuation signals for TSE:3034:
Debt-to-EBITDA: 0.63 (70% below median its 10-year median of 2.07)
GF Value™: 円2,300.17 vs. price of 円2,532.00 (10.1% above fair value)
Industry Position: 71.2% below the Healthcare Providers & Services median (#183 of 480)
No single metric tells the full story. See the TSE:3034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qol Holdings Co Ltd provides pharmacy services under health insurance and sells pharmaceutical products. Its mission is to create healthy and comfortable living environments for everybody in those communities. The company operates through: Pharmacy and BPO segments. Under the Pharmacy segment the company puts customers first in-store development strategy, which is based on building one-on-one relationships with drug-prescribing clinics and hospitals in order to get the pharmacy services that include medical information. The BPO contracting segment includes clinical trials and projects and develops pamphlets and websites for medical institutions to promote sales of pharmaceutical products and provide advice on proper pharmaceutical product.
88GF Score
Get the complete analysis for TSE:3034
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3034 has been successfully added to your 
